Rainbow Genomics Launches Polygenic and Trait Analysis for Obesity Management Using Whole Genome Sequencing

Genetic analysis of metabolic disorders, combined with assessment of nutrigenomic and exercise adaptation traits, enables lifestyle modification to reduce obesity

SAN FRANCISCO, CA, USA, Sept. 19, 2022 /EINPresswire.com/ — Rainbow Genomics, based in the United States and Hong Kong, launches comprehensive genetic analysis program for obesity, including genome sequencing to identify genomic variations associated with metabolic disorders, responses to food and nutrition, eating behavior and adaptation to exercise.

Obesity is considered by many physicians to be a chronic disorder, with body mass index (BMI) being one of the parameters indicating high body fat and overweight. BMI is highly inherited and more than 40-70% of BMI variability can be explained by genetic factors. Overweight people are likely to develop an increased risk of diabetes, heart disease, stroke and other metabolic diseases.

Some of the risk of obesity is conferred by genetic variants, including mutations in a single gene and polygenic changes associated with multiple genes. Additional risks of obesity are associated with genetic traits with strong behavioral characteristics, including appetite, eating behavior and adaptation to exercise.

The Rainbow Comprehensive Obesity Genetic Analysis Program is one of many reports provided by the Rainbow Adult 8000™ Whole Genome Sequencing Test. The test screens for single gene mutations and polygenic risks associated with metabolic disorders. In addition, several Asian-specific genetic traits are also determined, including genetic changes associated with BMI, appetite, eating behavior, food preferences, abnormalities in nutritional absorption, and adaptations to various forms of ‘exercise.

A comprehensive analysis of these results helps patients at risk of obesity adopt diet and lifestyle changes that could reduce their risk. Multi-faceted results are explained to patients in simple English and Chinese by a genetic counselor. Patients with disease-causing mutations associated with obesity, metabolic or cardiovascular disorders will also be referred to medical specialists for follow-up.

For more information on the Rainbow Obesity Comprehensive Genetic Analysis Program and the Rainbow Adult 8000™ Whole Genome Sequencing Test, please visit our website or email us at [email protected]

About the Rainbow Whole Genome Sequencing Test

The test provides five clinical reports:

1. Personal Health Assessment

• Cancer
• Cardiovascular disorders
• Abnormality of the endocrine system, including diabetes and fatty liver disease
• Sleep disorders
• Hearing and eye disorders
• Skeletal and bone disorders
• Immune system disorders
• Skin abnormality
• Auto-inflammatory disorders
• Behavioral abnormality
• Neurological disorders, including dementia and Alzheimer’s disease

2. Reproductive health assessment

• Male infertility
• Female infertility

3. Whole genome carrier status

• Carrier screening testing recommended by the American College of Obstetricians and Gynecologists and the American College of Medical Genetics

• Whole genome carrier analysis: mutations in 2,500 genes associated with recessive disorders that can be transmitted to the patient’s children

4. Common disease risk assessment

• Common complex diseases such as diabetes, heart attacks and strokes are mainly caused by changes in several genetic variants (polygenic risks). However, these variants are highly ethnic specific. Polygenic risk assessment for specific ethnic groups such as Asians is difficult because very few publications using Asian patients and healthy controls with statistical significance are available.

• Polygenic variants curated by Rainbow Genomics experts are highly ethnically specific and are supported by large-scale genome-wide association and replication studies using tens of thousands of patients and controls collectively drawn from Asia, USA and European countries.

5. Pharmacogenomic evaluation of 185 drugs to improve clinical outcomes

• For chronic conditions, it is essential to achieve risk reduction goals by improving adherence. Pharmacogenomic evaluation enables high therapeutic efficacy through minimization of drug side effects, resulting in better therapeutic outcomes.

6. Rainbow Obesity Comprehensive Genetic Analysis Program and Report

About Rainbow Genomics

Rainbow Genomics (www.rainbowgenomics.com) is committed to providing clinically validated genomics and proteomics testing to Asian, Caucasian, mixed race and local minority populations. The company offers high diagnostic success to physicians, enabling rapid treatment of patients who can benefit from immediate medical interventions.

Using a multi-platform technology approach, including proteomics, whole genome, whole exome, RNA, long read, methylation, single cell and Sanger sequencing, high-resolution microarray testing, and genotyping of high-density DNA arrays, and through multiple collaborations, Rainbow Genomics delivers diagnostic yield that meets or exceeds the highest standards reported by leading US and European medical institutions.

All Rainbow Genomics tests are performed in CLIA-certified and CAP-accredited high-complexity clinical laboratories. Patient privacy is protected by Rainbow’s HIPAA-compliant clinical testing process.

DANIEL UIS
Rainbow Genomics
+852 3481 0977
[email protected]


Source link

Comments are closed.